期刊
AMERICAN JOURNAL OF GASTROENTEROLOGY
卷 105, 期 5, 页码 1140-1141出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ajg.2010.15
关键词
-
Infliximab is a potent therapy for induction and maintenance of remission in Crohn's disease. Unfortunately, many patients lose response and/or develop allergic reactions caused by the chimeric antibody. By means of measuring the presence of antibodies against infliximab and the trough levels of the drug, it seems easier to predict whether patients will respond to intensified dose regimens or will rather benefit from a switch to alternative agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据